期刊文献+

葡萄糖转运蛋白4功能调节信号通路及其在药物研发中的应用 被引量:4

The signaling pathway for regulation of glucose transporter 4 and its application in drug development
原文传递
导出
摘要 葡萄糖转运蛋白4(glucose transporter 4,GLUT4)是胰岛素响应组织骨骼肌和脂肪组织内负责葡萄糖吸收的转运蛋白,它与生物体糖代谢过程密切相关.在肥胖或以胰岛素抵抗为特征的2型糖尿病等代谢性疾病中,GLUT4功能受损;反之,GLUT4功能的变化也能影响整体的糖代谢水平.本文概述了GLUT4的功能、组织分布、功能调节方式以及调控GLUT4功能的小分子化合物的研究进展,讨论了GLUT4在其他疾病中的应用,并展望了其未来研究方向. Glucose transporter 4(GLUT4) as a mediator for glucose up-take in skeletal muscle and adipose tissue plays important roles in whole-body glucose metabolism.Impaired glucose disposal is always observed in metabolic disease(such as obesity and type 2 diabetes),and glucose homeostasis can be impacted by alteration of GLUT4 function.Here,we summarize the function,tissue distribution and regulation pathway of GLUT4,and highlight the chemicals in restoring glucose homeostasis via modulating GLUT4 function.Finally,we also discuss the possible research focus of GLUT4 in the future and the association of GLUT4 with other diseases.
出处 《中国科学:化学》 CSCD 北大核心 2012年第12期1760-1773,共14页 SCIENTIA SINICA Chimica
基金 国家自然科学基金项目(91213306 21021063 81173105)资助
关键词 葡萄糖转运蛋白4(GLUT4) 胰岛素 糖尿病 葡萄糖转运蛋白膜转位 glucose transporter 4(GLUT4) insulin diabetes GLUT4 translocation
  • 相关文献

参考文献1

二级参考文献48

  • 1Muller WE, Sladic D, Zahn RK, Bassler KH, Dogovic N, Gerner H, et al. Avarol-induced DNA strand breakage in vitro and in Friend erythroleukemia cells. Cancer Res 1987; 47: 6565-71.
  • 2Muller WE, Dogovic N, Zahn RK, MaidhofA, Diehl-Seifert B, Becket C, et al. Inhibition of mitosis by avarol, a natural product isolated from the sponge Dysidea avara. Basic Appl Histochem 1985; 29: 321-30.
  • 3Yoo HDL, Sanghara D, Daley J, van Soest D, Andersen R, Isoarenarol RJ. A new protein kinase inhibitor from the marine sponge Dysidea arenaria. Pharm Biol 2003; 41: 223-5.
  • 4Sarin PS, Sun D, Thornton A, Muller WE. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. J Natl Cancer Inst 1987; 78: 663-6.
  • 5Lucas R, Giannini C, D'Auria MV, Paya M. Modulatory effect of bolinaquinone, a marine sesquiterpenoid, on acute and chronic inflammatory processes. J Pharmacol Exp Ther 2003; 304:1172- 80.
  • 6Giannini C, Debitus C, Lucas R, Ubeda A, Paya M, Hooper JN, et al. New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte functions. J Nat Prod 2001; 64: 612-5.
  • 7Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH. Marine sponges as pharmacy. Mar Biotechnol (NY) 2005, 7: 142-62.
  • 8Proksch P, Edrada RA, Ebel R. Drugs from the seas-current status and microbiological implications. Appl Microbiol Biotechnol 2002; 59: 125-34.
  • 9Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-15.
  • 10Haffner SM, Stern MP, Dunn J, Mobley M, Blackwell J, Bergman RN. Diminished insulin sensitivity and increased insulin response in nonohese, nondiahetic Mexican Americans. Metabolism 1990;39: 842-7.

共引文献5

同被引文献66

引证文献4

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部